Connect your AI

Embecta Corp. EMBC 2029

2029 at other companies

Lifecore Biomedical, Inc.LFCR

——

ICU MedicalICUI

——

AbbottABT

——

Other financials

Income statement

Revenue$221.8M-14.4%

Gross profit$127.8M-22.1%

Operating income$35.0M-44.4%

Net income-$4.1M-117%

EPS (diluted)-$0.07-118%

Balance sheet

Cash & equivalents$193.4M-8.9%

Total debt$1.4B-12.5%

Total equity-$626.1M+15.0%

Total assets$1.0B-8.1%

Cash flow

Operating cash flow$31.1M-2.2%

CapEx$500.0K+400%

Free cash flow$30.6M-3.5%

Valuation

Market cap$193.41M-64.3%

Enterprise value$1.37B-24.8%

P/E1.7×-4.8×

P/S0.2×-0.3×

Profitability

Gross margin61.9%-1.6pp

Operating margin25.8%+9.7pp

Net margin10.7%+5.8pp

FCF margin19.6%+16.0pp

Returns & leverage

Return on equity71.9%—

Debt / equity0×—

Current ratio2.5×0.0×

Where this comes from

Reported directly by Embecta Corp. in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree.

The official record: Embecta Corp.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Embecta Corp.'s 2029.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Embecta Corp.'s 2029?: Embecta Corp. (EMBC) reported 2029 of $618M in Q1 2026.
How has Embecta Corp.'s 2029 changed year-over-year?: Embecta Corp.'s 2029 increased by 6405.3% year-over-year, from $9.5M to $618M.